Immunome IMNM Business Segments — Operating Income

Similar metrics at other companies

QURESingle Reportable — Operating Income

-$39.21M-14.3%

LQD

LQDASingle Reportable — Operating Income

$61.5M+274%

ALMSSingle Reportable — Operating Income

-$98.41M+3.1%

BOOTSingle Reportable — Operating Income

$57.22M+15.2%

POWISingle Reportable — Operating Income

$1.45M-78.4%

POOLReportable — Operating Income

$82.61M+6.5%

Questions, answered.

What is Immunome's business segments — operating income?

Immunome (IMNM) reported business segments — operating income of -$59.33M in Q1 2026.

How has Immunome's business segments — operating income changed year-over-year?

Immunome's business segments — operating income decreased by 32.9% year-over-year, from -$44.64M to -$59.33M.

What is the long-term trend for Immunome's business segments — operating income?

Over 2 years (2023 to 2025), Immunome's business segments — operating income has grown at a 43.0% compound annual growth rate (CAGR), from -$109.53M to -$224.11M.

What does business segments — operating income mean?

Calculated as the segment's revenue minus its total operating expenses, representing the profitability of the core business activities before interest and taxes. For early-stage companies, this is typically a loss, reflecting the investment phase of the business. It serves as the primary gauge for the segment's operational viability and path toward self-sustainability.